INTRODUCTION: Thefirst line treatment landscape for patients with NSCLC harboring sensitizing AREASCOVERED: Thispaper reviews and compares the pivotal studies that led to the approval ofcombination treatment with a focus on the efficacy and safety of amivantamabplus lazertinib in the front-line setting. The literature reviewed in thispaper primarily includes key studies published in well-established journals andoncological conferences, such as ASCO, ESMO, and NEJM, between 2018 and 2024. EXPERTOPINION: Recent advancements,including the results of FLAURA-2 and MARIPOSA, have introduced combinationtherapies that demonstrate enhanced efficacy.